$NVCR 0.52 Developing

Notable posts

• @wallstengine bullish 39 eng

  NOVOCURE $NVCR Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $183.6M (Est. $172.7M) 🟢; +16% YoY 🔹 EPS: -$0.13 (Est. -$0.33) 🟢 🔹 Gross Margin: 78% vs. 74% YoY 🔹 Global Active Patients: 5,128; +18% YoY Raises FY26 Guidance: 🔹 Revenue: $710M-$725M (Est. $708.7M) 🟢 🔹 Adj EBITDA: $0-$15M (Prior: -$15M to $0) 🟢 Other Highlights: 🔹 Adj EBITDA: $10.8M 🔹 Optune Pax Active Patients: 285 🔹 Optune Pax Prescriptions: 418 🔹 Cash and Investments: $440.6M 🔸 Received CE Mark for Optune Pax in locally advanced pancreatic cancer.

  view on X →
• @tenet_research neutral 25 eng

  Tenet Market Wake-Up Summary 📷📷 June.18.26 $SPX $AAPL $INTC $AVGO $OKLO $LEU $META $TSLA $NOK $RUM $UUUU $QBTS $ONDS $ZETA $PFE $SPCX $TSEM $MRVL $SWBI $ACN $KR $ALB $ENPH $QURE $CEG $TLN $CURB $ENGN $INTU $CAST $LNKS $LPA $NVCR $LEGN @ripster47 | @tenet_research | @TenetCharts

  view on X →
• @TENETTRADEGROUP neutral 23 eng

  Tenet Pre-Market Movers June.18.26 $CAST $LNKS $LPA $SPRO $SWBI $RUM $BGDE $HIVE $LEU $INTC $AXTI $BTGO $SB $TSEM $OKLO $BEAM $ODTX $QBTS $ONDS $NVCR $ELTX $ACN $LEGN $CTSH $STLD $KR @ripster47 | @tenet_research | @TenetCharts https://t.co/6lQxGt1WUE

  view on X →